期刊
CURRENT OPINION IN IMMUNOLOGY
卷 54, 期 -, 页码 123-129出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2018.06.002
关键词
-
类别
资金
- European Commission under the Horizon 2020 program H2020 MSCA-ITN GA 675278 EDGE
- Dr. FP Fischer Foundation (Utrecht, The Netherlands)
CRISPR/Cas9 is a technology that allows for targeted and precise genome editing in eukaryotic cells. The technique has changed the landscape of molecular biology and may be applied to repair genetic disorders in future therapies. Besides targeting the human genome, it can be used to cleave and edit viral DNA present in infected cells, and as such provides a promising new strategy for anti-viral therapy. Here, we discuss recent studies on the use of anti-viral CRISPRs to target pathogenic human viruses, with a focus on in vivo studies, challenges, and potential for future clinical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据